Zacks: Analysts Expect West Pharmaceutical Services Inc. (WST) Will Announce Earnings of $0.62 Per Share
Equities analysts expect West Pharmaceutical Services Inc. (NYSE:WST) to report earnings of $0.62 per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for West Pharmaceutical Services’ earnings. The lowest EPS estimate is $0.61 and the highest is $0.63. West Pharmaceutical Services posted earnings per share of $0.54 during the same quarter last year, which would suggest a positive year over year growth rate of 14.8%. The company is expected to issue its next earnings results before the market opens on Thursday, February 15th.
On average, analysts expect that West Pharmaceutical Services will report full-year earnings of $2.76 per share for the current year, with EPS estimates ranging from $2.75 to $2.77. For the next year, analysts expect that the business will post earnings of $2.90 per share, with EPS estimates ranging from $2.79 to $2.99. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow West Pharmaceutical Services.
Several equities analysts recently issued reports on WST shares. Zacks Investment Research upgraded West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research note on Friday, January 26th. Bank of America cut West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price objective on the stock. in a research note on Tuesday, October 17th. Wells Fargo & Co raised their price objective on West Pharmaceutical Services from $105.00 to $112.00 and gave the stock an “outperform” rating in a research note on Friday, October 27th. Finally, Goldman Sachs Group started coverage on West Pharmaceutical Services in a research note on Wednesday, January 24th. They set a “neutral” rating and a $110.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $108.17.
A number of hedge funds and other institutional investors have recently modified their holdings of WST. Citigroup Inc. increased its position in West Pharmaceutical Services by 95.1% in the second quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 765 shares during the period. Nomura Holdings Inc. acquired a new stake in West Pharmaceutical Services in the second quarter worth $201,000. Grandfield & Dodd LLC acquired a new stake in West Pharmaceutical Services in the third quarter worth $201,000. Private Advisor Group LLC acquired a new stake in West Pharmaceutical Services in the third quarter worth $202,000. Finally, Alps Advisors Inc. acquired a new stake in West Pharmaceutical Services in the fourth quarter worth $206,000. 92.69% of the stock is currently owned by hedge funds and other institutional investors.
Shares of West Pharmaceutical Services (NYSE WST) traded up $0.83 on Wednesday, reaching $91.25. The company had a trading volume of 377,092 shares, compared to its average volume of 353,120. West Pharmaceutical Services has a 52-week low of $77.97 and a 52-week high of $103.36. The company has a market capitalization of $6,713.95, a PE ratio of 36.35, a PEG ratio of 1.92 and a beta of 1.04. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.59 and a quick ratio of 1.87.
The business also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Thursday, January 18th were given a $0.14 dividend. This represents a $0.56 annualized dividend and a yield of 0.61%. The ex-dividend date was Wednesday, January 17th. West Pharmaceutical Services’s dividend payout ratio is presently 22.31%.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.